HeartBeam Receives FDA Breakthrough Device Designation for Heart Attack Assessment

The designation gives HeartBeam prioritized FDA interaction as it prepares a pivotal study of its 3D ECG technology for assessing suspected heart attacks outside traditional medical settings. Key Investor TakeawaysHeartBeam (NASDAQ:BEAT) received FDA Breakthrough Device Designation for using its 3D ECG technology to assess potential heart attacks at home.